The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://kiararkxu058773.prublogger.com/37995147/glp-3-retatrutide-a-comparative-analysis